secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vera Therapeutics, Inc. (VERA)
CIK:        0001831828
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001193125-24-014808
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vera Therapeutics reports positive 72-week Phase 2b atacicept data with eGFR stabilization in IgAN
--------------------------------------------------------------------------------

- Atacicept 150mg for 72 weeks: 62% reduction in Gd-IgA1, hematuria to 19%, 48% reduction in UPCR (PP analysis).
- eGFR stable with 0 mL/min/1.73m² change from baseline; placebo-to-atacicept switchers halted eGFR decline (-3.2 vs -4.9 at 36wks).
- Safety consistent with prior trials; generally well-tolerated in OLE.
- Phase 3 ORIGIN 3 enrollment on track for H2 2024; topline data expected H1 2025; BLA submission planned H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524014808/0001193125-24-014808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831828/000119312524014808/d717089d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-014808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer